Clinical trials: Patient With Schizophrenia Spectrum Disorder
Overweight and Obesity, Metabolic Cardiovascular Syndrome
The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations.
- Conditions
- Overweight and Obesity, Metabolic Cardiovascular Syndrome, Schizophrenia, Disorganized
- Trial name
- NCT06789471
- Testing
- psyllium husk
- Where
- Taiwan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ru-Shin Zhang
Schizophrenia, Episodic Memory Deficits
Retrieval Practice and Schizophrenia
When people are tested on a previously learned material, they will later remember it better even when compared to a condition where they can re-study it.
- Trial name
- NCT02108899
- Testing
- Retrieval practice effect using descriptive stories and free-call tests without feedback
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia; Negative Type
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Schizophrenia patients commonly present with persistent negative symptoms which remain the main reason for dysfunction after recovery from an acute episode of psychotic symptoms.
- Trial name
- NOBLE-TMS (NCT06351514)
- Testing
- Accelerated iTBS
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Institute of Mental Health, Singapore
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Violence
Prediction of Violent Behavior in Patients With Schizophrenia by Multimodal Machine Learning
Patients with schizophrenia have a higher risk of committing violent crimes than the general population, and the relative risk of violence against others is four times higher than the general population.
- Trial name
- NCT04520399
- Testing
- none intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder
The Joint Crisis Plan = SOS Plan is a reference to a particular form of psychiatric advance directive which involves the patient, the healthcare team, their relatives and a third party caregiver as intermediary for the project.
- Trial name
- SOS (NCT02627716)
- Testing
- SOS Plan
- Where
- 4 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Lille
Randomized Controlled Trial
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
This study will explore the effect of Rumination-Focused Cognitive Behaviour Therapy on depressive symptoms in patients with schizophrenia for three months.
- Trial name
- NCT04442893
- Testing
- Rumination-Focused Cognitive Behaviour Therapy, Health Education programme
- Where
- Taiwan
- Volunteers
- 85 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
Potential Intervention Strategy With Folic Acid and Vitamin B12 in Patients With Schizophrenia
The investigators study aims are: 1. To investigate folate, vitamin B12, and homocysteine levels in patients with schizophrenia. 2.
- Trial name
- NCT02916121
- Testing
- folic acid 5 mg/cap
- Where
- Taiwan
- Volunteers
- 88 people
- Sponsor
- Taipei Medical University WanFang Hospital
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Indication for Modification of Patient Cognitive Status
Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia
The purpose of this study was to develop an integrative intervention for schizophrenia taking into account previous efficacious therapies.
- Trial name
- NCT01279070
- Testing
- Repyflec cognitive remediation training
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundació Sant Joan de Déu
Depression - Major Depressive Disorder, Schizophrenia Disorders
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also…
- Conditions
- Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)
- Trial name
- NCT06729541
- Testing
- Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Schizophrenia
The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics
Purpose To evaluate the efficacy and safety of once-daily quetiapine extended release (XR) in patients with schizophrenia switched from other antipsychotics which were suboptimal due to insufficient efficacy or insufficient…
- Trial name
- NCT02142556
- Testing
- Administration of quetiapine XR
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia
The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study.
- Trial name
- NCT03080194
- Testing
- paliperidone palmitate, control group
- Volunteers
- 150 people
- Sponsor
- Maosheng Fang
Schizophrenia
An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
The purpose of this study is to assess the safety, effectiveness, and plasma concentration of paliperidone (an antipsychotic medication) given once daily in the treatment of patients with schizophrenia
- Trial name
- NCT00257023
- Testing
- paliperidone
- Volunteers
- 52 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia
A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric…
- Trial name
- NCT01606254
- Testing
- Paliperidone palmitate
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
The purpose of this study is to determine whether pregnenolone will demonstrate significant improvements in cognitive functioning and negative symptoms compared to patients receiving placebo.
- Trial name
- NCT00894842
- Testing
- Pregnenolone
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- National Research Foundation, Singapore
Schizophrenia
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Trial name
- NCT00080327
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Establishment of the Early Intervention Program for Patients With Schizophrenia
Schizophrenia is a severe mental illness, which has a prodromal phase of 1-2 years prior to the onset of the illness. During the prodromal phase, patients might show maladaptation and/or poor social functioning.
- Trial name
- NCT00172770
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Treatment of Schizophrenic Patients With Ziprasidone
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
- Trial name
- TRITON (NCT00579670)
- Testing
- Ziprasidone
- Where
- 20 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.